Navigation Links
Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses
Date:11/16/2010

PHILADELPHIA, Nov. 16, 2010 /PRNewswire/ -- Berger & Montague, P.C. and Brower Piven, A Professional Corporation, Co-Lead Counsel for Lead Plaintiff and the Class in the Hemispherx Biopharma, Inc. securities class-action suit, announced the following:IN THE UNITED STATES DISTRICT COURTFOR THE EASTERN DISTRICT OF PENNSYLVANIA:IN RE HEMISPHERX:BIOPHARMA, INC. LITIGATION:CIVIL ACTION NO.  09-CV-5262-PSD:SUMMARY NOTICE OF PROPOSED SETTLEMENT, SETTLEMENT FAIRNESS HEARING, AND MOTION FOR AWARD OF ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSESTO:ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE COMMON STOCK OF HEMISPHERX BIOPHARMA, INC. ("HEMISPHERX") FROM FEBRUARY 18, 2009 THROUGH AND INCLUDING DECEMBER 1, 2009 (THE "CLASS PERIOD")PLEASE READ THIS NOTICE CAREFULLYIF YOU ARE A MEMBER OF THE CLASS DESCRIBED IN THIS NOTICE, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT AND YOU MAY BE ENTITLED TO RECEIVE PAYMENTS PURSUANT TO A PROPOSED SETTLEMENTPursuant to Rule 23 of the Federal Rules of Civil Procedure and by Order of the United States District Court for the Eastern District of Pennsylvania dated October 20, 2010, a hearing will be held on January 20, 2011 at 10:00 a.m. in Courtroom 6B, United States Courthouse, 601 Market Street, Philadelphia, PA 19106, to determine (1) whether the proposed Settlement (the "Settlement") of the above-captioned action ("Action") for $3,600,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the motion of Co-Lead Counsel for an award of attorneys' fees and reimbursement of expenses should be approved; and (3) whether the Action should be dismissed with prejudice.

If you have not yet received in the mail the long-form version of the Notice of Pendency of Class Action and Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses (the "Notice") and Proof of Claim and Release Form ("Proof of Claim Form"), you may obtain copies of these documents by contacting: In re Hemispherx Biopharma, Inc. Litigation, c/o Heffler, Radetich & Saitta, LLP, P.O. Box 58578, Philadelphia, PA 19102-8578.  Copies of the Notice and Proof of Claim Form may also be downloaded from the Claims Administrator's website, www.heb.hrsclaims.com.  If you are a Class Member, in order to be eligible to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim Form no later than February 19, 2011, establishing that you are entitled to recovery.  

If you have not obtained a copy of the Notice, you are urged to do so.  If the proposed Settlement is approved, you will be bound by the Order and Final Judgment whether or not you submit a Proof of Claim Form.If you desire to be excluded from the Class, you must submit a request for exclusion by December 29, 2010, in the manner and form explained in the Notice.  All Class Members who do not request exclusion from the Class will be bound by any judgment entered in the Action, including without limitation, the Order of Final Judgment and Dismissal with Prejudice, whether or not you timely submit a Proof of Claim Form.

Any objection to the proposed Settlement, Plan of Allocation, or application for attorneys' fees and reimbursement of litigation expenses must be filed with the Court and delivered to counsel for the parties not later than January 6, 2011 in the manner and form set forth in the Notice.

Inquiries, other than requests for the Notice and Proof of Claim Form, may be made to Co-Lead Counsel:

BERGER & MONTAGUE, P.C.

BROWER PIVENAttn: Sherrie R. Savett

A Professional Corporation1622 Locust Street

Attn:  David A.P. BrowerPhiladelphia, PA 19103

488 Madison Ave., Eighth FloorNew York, NY 10022PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE.  By Order of The United States District Court for the Eastern District of Pennsylvania


'/>"/>

SOURCE Berger & Montague, P.C.; Brower Piven
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
2. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
3. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
4. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
5. EntreMed Receives Notice of NASDAQ Compliance
6. Caliper Life Sciences Third Quarter 2010 Financial Results Conference Call Notice
7. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
8. China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards
9. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
10. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology
11. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):